glaucoma
Conditions
Interventions
None listed
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1.Surgical patients who will undergo glaucoma surgery(trabeculectomy, trabeculotomy, trabecutome, etc) or cataract surgery. 2.Performance Status: 0 ~ 4. 3.Patients who are 20 years of age or more. 4.Patients who understood and signed letter of consent.
Exclusion criteria
Exclusion criteria: 1.Patients undergoing the treatment for malignant tumor. 2.Patients undergoing hemodialysis. 3.Patients with severe systemic disease. 4.Patients who are inadequate for this study on the based on physician's discretion.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| [Aqueous humor, blood, Urine] 1.Abundance of nucleic acid, protein, lipid, metabolite, etc 2.Abundance of biologically active substance(cytokine, prostaglandin, endothelin, etc) 3.Abundance of trace metal(Zinc, Mercury, etc) 4.Comprehensively Profile of autoantibody 5.Transcript abundance [Ocular tissue(sclera, Schlemm's canal, iris, trabecular meshwork)] 1.Abundance of nucleic acid, protein, lipid, metabolite, etc 2.Abundance of biologically active substance(cytokine, prostaglandin, endothelin, etc) 3.Abundance of trace metal(Zinc, Mercury, etc) 4.Comprehensively Profile of autoantibody 5.Transcript abundance 6.Abundance of glycosaminoglycan and glycosaminoglycan-degrading enzyme 7.Evaluating the tissue structure [Ocular tissue(tenon's fibroblast cells)] 1.Abundance of nucleic acid, protein, lipid, metabolite, etc 2.Abundance of biologically active substance(cytokine, prostaglandin, endothelin, etc) 3.Transcript abundance 4.Evaluating cell formation, cell proliferation and cell contraction In addition to the above, the relationship beteween above the factor and clinical information(age, sex, visual acuity intraocular pressure, visual field, etc). | — |
Countries
Japan
Contacts
Tohoku University Graduate School of Medicine Department of Ophthalmology